At the signing ceremony (Photo: VNA) Hanoi (VNA) – Genuone Sciences,
the Republic of Korea’s leading pharmaceutical company, announced on February 26 that it signed a
business agreement with Vietnam’s (IMP) on the
transfer of technology for seven products, including medications for the treatment of cardiovascular and diabetes-related diseases.
Genuone Sciences will support the entire
process from production to supply and distribution of these products.
In addition to the existing method of
distributing domestically produced products to Vietnam, the Korean company can
now produce and supply products directly in the Southeast Asian country.
Samsoo Lee, CEO of Inc,
described the strategic cooperation with Imexpharm as an important one that
helps Genuone gradually access the Vietnamese pharmaceutical market, a
potential and dynamic market in the Southeast Asia region.
To date, Imexpharm owns four manufacturing
clusters, including three with eleven production
lines that meet EU-GMP standards. This has made Imexpharm the largest
pharmaceutical manufacturing company with EU-GMP manufacturing clusters and the
highest number of EU-GMP production lines. /.
Source: VietnamPlus
